Phase I Study of the Combination of Vemurafenib With Carboplatin and Paclitaxel in Patients With Advanced Malignancy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 May 2017
At a glance
- Drugs Vemurafenib (Primary) ; Carboplatin; Paclitaxel
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 19 May 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 18 May 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Apr 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.